Risk Variable Selection After PCI Remains Highly Inconsistent
Prognostic modeling after percutaneous coronary intervention has grown into a crowded field, but the basic inputs are far from standardized. A systematic review examined how investigators reported variables in risk scores and prediction models for patients after PCI, and the picture that emerges is one of substantial heterogeneity. Across 981 records, 212 articles were eligible, representing 180 distinct scores or models. The review focused on English-language studies that developed, validated, or compared prognostic tools for post-PCI outcomes and then mapped which clinical variables kept recurring across models.
The most common predictors were familiar bedside markers: sex or gender, age, diabetes, cerebrovascular disease, peripheral vascular disease, acute coronary syndrome, heart failure, serum creatinine or estimated glomerular filtration rate, left ventricular ejection fraction, and culprit artery. Each of those variables carries obvious mechanistic weight in coronary disease. Age and diabetes capture cumulative vascular injury; renal dysfunction reflects systemic atherosclerotic burden and complicates antithrombotic and contrast exposure; low ejection fraction marks impaired reserve after ischemic injury; and culprit-vessel anatomy defines the immediate ischemic territory and the procedural target.
Ethnic Differences Appeared in Core Model Inputs
A more striking finding came from the comparison of models developed in Caucasian versus non-Caucasian populations. Of the included scores and models, 94 were classified as Caucasian and 86 as non-Caucasian, and significant differences emerged in several variables: systolic blood pressure, heart rate, serum creatinine or eGFR, acute coronary syndrome presentation, ST-segment deviation, and culprit artery. Those are not cosmetic differences. They point to the possibility that model builders are not just selecting variables differently, but are also constructing prediction tools in populations with distinct clinical profiles, referral pathways, baseline physiology, and event patterns.
Blood pressure and heart rate can function as broad surrogates for hemodynamic stress and sympathetic activation, both of which influence early and late post-PCI risk. ST-segment deviation and ACS presentation reflect ischemic severity at the time of revascularization, while culprit artery distribution can mirror differences in coronary anatomy, disease pattern, and procedural complexity. When such variables diverge between populations, the resulting scores may not transport cleanly across settings, especially if a model calibrated in one group is applied to another without recalibration or external validation. The review places that problem in plain view.
One model built for one population may not behave like the same model in another.
Wide Model Diversity Raises Questions About Comparability
The review’s descriptive synthesis makes clear that the field has not converged on a single framework for post-PCI prognostication. Instead, investigators have produced a large number of distinct scores and models, many of which overlap in some variables while diverging in others. That pattern suggests a discipline still shaped by local data availability, institutional preference, and the practical limits of retrospective derivation cohorts. It also means that two tools with similar labels may be based on different clinical assumptions and may not estimate the same risk horizon.
This matters at the bedside because risk scores are often used to guide intensity of follow-up, preventive therapy, and patient counseling after PCI. If one model places greater weight on renal function and another emphasizes hemodynamic variables, clinicians may receive different risk estimates for the same patient. The biologic logic behind each variable is sound in isolation, but prognostic medicine depends on the entire model architecture, not simply on whether each component is clinically plausible. Prediction tools only earn trust when they are built, tested, and reported with enough consistency to support comparison across populations.
High Risk of Bias Still Dominates the Evidence Base
Methodologic quality was another major concern. The review assessed risk of bias using PROBAST in a random sample of 20 models, and 70% were judged to be at high risk of bias. That is an uncomfortably large proportion for a literature that is increasingly used to shape clinical decision-making, research prioritization, and risk stratification. High bias in prediction modeling often traces back to familiar problems: small samples, selective reporting, weak handling of missing data, inadequate validation, and overfitting. Even when a model looks statistically impressive in derivation, it can fail when confronted with new patients and a different case mix.
The implication is straightforward. A risk score after PCI is only as reliable as the methods used to create it, and this review suggests that methodological rigor has not kept pace with the expansion of the field. The presence of many models does not guarantee better prediction. In fact, a crowded literature with inconsistent variable selection can make clinical adoption harder, not easier, because clinicians are left to choose among tools that may not be comparable in scope or performance.
What the Review Means for Post-PCI Prognostication
At a practical level, the findings argue for tighter standards in how prognostic variables are chosen and reported. Models should be transparent about why specific predictors were selected, how missing values were handled, whether candidate variables were prespecified or data-driven, and how well the model performed outside its derivation cohort. The ethnic differences identified in the review also suggest that future work should pay closer attention to transportability rather than assuming that one score fits all coronary populations. For PCI prognosis, transportability is not a minor statistical issue; it determines whether a model can be used safely in daily care.
The review also reinforces the value of clinically grounded predictors such as renal function, ventricular performance, ischemic presentation, and culprit-vessel anatomy. Those variables remain biologically credible because they track the severity of vascular disease, myocardial damage, and procedural complexity. Yet biological plausibility is only part of the equation. Predictive accuracy depends on how those variables interact, how they are measured, and how a model is validated across settings that differ in patient mix and treatment patterns.
For now, the literature after PCI looks extensive but uneven. The model count is high, the variable sets are inconsistent, and high risk of bias remains common. Until future prognostic studies use more rigorous derivation and validation methods, the field will continue to produce tools that are easy to publish and harder to trust.